Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia


Klinik

Standort der Organisation:
Brescia, Italien


Publikationen in Kooperation mit FAU-Wissenschaftern


Elhai, M., Boubaya, M., Distler, O., Smith, V., Matucci-Cerinic, M., Alegre Sancho, J.J.,... Allanore, Y. (2019). Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: A prospective cohort study. Annals of the Rheumatic Diseases. https://dx.doi.org/10.1136/annrheumdis-2018-214816
Biermann, M., Boeltz, S., Pieterse, E., Knopf, J., Rech, J., Bilyy, R.,... Munoz, L.E. (2018). Autoantibodies Recognizing Secondary NEcrotic Cells Promote Neutrophilic Phagocytosis and Identify Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 9. https://dx.doi.org/10.3389/fimmu.2018.00989
Ivanovski, I., Djuric, O., Caraffi, S.G., Santodirocco, D., Pollazzon, M., Rosato, S.,... Garavelli, L. (2018). Phenotype and genotype of 87 patients with Mowat-Wilson syndrome and recommendations for care. Genetics in Medicine, 20(9), 965-975. https://dx.doi.org/10.1038/gim.2017.221
Jaeger, V.K., Siegert, E., Hachulla, E., Airo, P., Valentini, G., Matucci-Cerinic, M.,... Walker, U.A. (2018). Racial differences in SSc disease presentation: a European scleroderma trials and research group (EUSTAR) study. (pp. 9S-9S).
Elhai, M., Distler, O., Smith, V., Matucci-Cerinic, M., Alegre-Sancho, J.J., Truchetet, M.-E.,... Allanore, Y. (2018). RITUXIMAB IN SYSTEMIC SCLEROSIS : SAFETY AND EFFICACY DATA FROM THE EUSTAR NETWORK. (pp. 122-122).
Elhai, M., Meune, C., Boubaya, M., Avouac, J., Hachulla, E., Balbir-Gurman, A.,... Allanore, Y. (2017). Mapping and predicting mortality from systemic sclerosis. Annals of the Rheumatic Diseases. https://dx.doi.org/10.1136/annrheumdis-2017-211448
Ferreri, A.J.M., Cwynarski, K., Pulczynski, E., Fox, C.P., Schorb, E., La Rosee, P.,... Illerhaus, G. (2017). Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal L. Lancet Haematology, 4(11), e510-e523. https://dx.doi.org/10.1016/S2352-3026(17)30174-6
Ferreri, A.J.M., Cwynarski, K., Pulczynski, E., Ponzoni, M., Deckert, M., Politi, L.S.,... Illerhaus, G. (2016). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematology, 3(5), e217-27. https://dx.doi.org/10.1016/S2352-3026(16)00036-3
Jaeger, V.K., Wirz, E.G., Allanore, Y., Rossbach, P., Riemekasten, G., Hachulla, E.,... Walker, U.A. (2016). Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS ONE, 11(10), e0163894. https://dx.doi.org/10.1371/journal.pone.0163894
Fickentscher, C., Magorivska, I., Janko, C., Biermann, M., Bilyy, R., Nalli, C.,... Herrmann, M. (2015). The Pathogenicity of Anti-β2GP1-IgG Autoantibodies Depends on Fc Glycosylation. Journal of immunology research, 2015, 638129. https://dx.doi.org/10.1155/2015/638129
Lopez-Isac, E., Bossini-Castillo, L., Simeon, C.P., Victoria Egurbide, M., Jose Alegre-Sancho, J., Luis Callejas, J.,... Martin, J. (2014). A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. Arthritis Research & Therapy, 16(1), R6. https://dx.doi.org/10.1186/ar4432
Mayes, M.D., Bossini-Castillo, L., Gorlova, O., Martin, J.E., Zhou, X., Chen, W.V.,... Martin, J. (2014). Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. American Journal of Human Genetics, 94(1), 47-61. https://dx.doi.org/10.1016/j.ajhg.2013.12.002

Zuletzt aktualisiert 2016-28-09 um 08:08